ProfileGDS5678 / 1419149_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 83% 85% 80% 87% 82% 82% 81% 79% 79% 81% 81% 83% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7864488
GSM967853U87-EV human glioblastoma xenograft - Control 26.1655583
GSM967854U87-EV human glioblastoma xenograft - Control 36.394485
GSM967855U87-EV human glioblastoma xenograft - Control 45.8593580
GSM967856U87-EV human glioblastoma xenograft - Control 56.7363887
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7115682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8281382
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8180981
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4556679
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6017179
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8409481
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.79681
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0622383
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7092581